![NGS and precision oncology in Australia: insights from Profs Peter Gibbs and Svetlana Cherepanoff New Project 3 New Project 3](https://clinicalvalue.com/wp-content/uploads/2023/08/New-Project-3.png)
NGS and precision oncology in Australia: insights from Profs Peter Gibbs and Svetlana Cherepanoff
In this article, Prof Peter Gibbs and Prof Svetlana Cherepanoff discuss the issues surrounding the clinical integration of NGS in Australia.
READ MOREYou are about to leave the Clinical Value website now.
In this article, Prof Peter Gibbs and Prof Svetlana Cherepanoff discuss the issues surrounding the clinical integration of NGS in Australia.
READ MORENGS and digital applications for oncology management can help improve early cancer detection and prevention, reducing human and economic costs of the cancer. In this article,…
READ MOREIn this article, Dr Amit Rauthan shares insights on the challenges and opportunities for greater NGS adoption in India.
READ MOREThe integration of next-generation sequencing (NGS) comprehensive gene profiling (CGP) into clinical practice is playing an increasingly important role in oncology. Therefore, the HKU-HKSH Multi-disciplinary Molecular…
READ MOREIn this article, Dr Lam Tai-Chung shares how his institution has had first-hand experience of landmark cases and outstanding treatment responses from using NGS in seemingly…
READ MOREIn this article, Dr David Tan discusses the potential of NGS in Singapore, where the adoption of this technology is only just beginning to take root.
READ MOREIn this article, Prof Jee Hyun Kim explains her clinical experiences of NGS, and how she sees it evolving within South Korea’s innovative healthcare ecosystem.
READ MOREWhile precision oncology has shown great promise, there are still barriers to its implementation, such as data fragmentation, staff shortages and time, funding, and lack of…
READ MOREThese recommendations provide a critical guidance from NGS panel testing to final treatment decision based on MTB discussion.
READ MORE